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Abstract
Genome-wide association studies (GWAS) have begun to identify the common genetic component to ischaemic stroke (IS).
However, IS has considerable phenotypic heterogeneity. Where clinical covariates explain a large fraction of disease risk,
covariate informed designs can increase power to detect associations. As prevalence rates in IS are markedly affected by
age, and younger onset cases may have higher genetic predisposition, we investigated whether an age-at-onset informed
approach could detect novel associations with IS and its subtypes; cardioembolic (CE), large artery atherosclerosis (LAA) and
small vessel disease (SVD) in 6,778 cases of European ancestry and 12,095 ancestry-matched controls. Regression analysis to
identify SNP associations was performed on posterior liabilities after conditioning on age-at-onset and affection status. We
sought further evidence of an association with LAA in 1,881 cases and 50,817 controls, and examined mRNA expression
levels of the nearby genes in atherosclerotic carotid artery plaques. Secondly, we performed permutation analyses to
evaluate the extent to which age-at-onset informed analysis improves significance for novel loci. We identified a novel
association with an MMP12 locus in LAA (rs660599; p = 2.561027), with independent replication in a second population
(p = 0.0048, OR(95% CI) = 1.18(1.05–1.32); meta-analysis p = 2.661028). The nearby gene, MMP12, was significantly
overexpressed in carotid plaques compared to atherosclerosis-free control arteries (p = 1.2610215; fold change = 335.6).
Permutation analyses demonstrated improved significance for associations when accounting for age-at-onset in all four
stroke phenotypes (p,0.001). Our results show that a covariate-informed design, by adjusting for age-at-onset of stroke,
can detect variants not identified by conventional GWAS.
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Introduction
Genome-wide association studies (GWAS) in ischaemic stroke
have begun to identify the common genetic variants that confer
risk of the disease. However, there is considerable heterogeneity
present in stroke phenotypes: GWAS analyses have primarily
looked at the three main subtypes; cardioembolic (CE), large
artery atherosclerosis (LAA) and small vessel disease stroke (SVD).
Within these subtype analyses, numbers of cases are smaller, but
the expectation is that the effects of SNPs identified within the
subtypes will be considerably larger. Indeed, all validated GWAS
SNPs for ischaemic stroke to date have been stroke subtype-
specific [1,2,3,4,5], indicating the importance of subtyping of
cases.
Clinical risk factors are important in stroke; as many as 77% of
first-ever stroke patients are hypertensive [6], and other factors
such as diabetes mellitus and elevated serum cholesterol confer a
considerable proportion of disease risk [7]. These risk factors
increase in prevalence in older age groups, suggesting older stroke
patients may have a reduced stroke-specific genetic contribution.
MMP12 and Large Artery Atherosclerotic Stroke
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Indeed, IS is uncommon in individuals below middle age, but
increases greatly in prevalence beyond the age of 65 [8], with a
lifetime risk of 1 in 5 for women and 1 in 6 for men [9].
Under the assumptions of the liability threshold model, the low
prevalence of IS in younger age ranges suggests that individuals
who do suffer strokes in this age group are likely to have an
increased genetic predisposition. This is supported by family
history data; with stronger family history seen in younger onset
cases [10,11,12], and twin studies [13], which suggest that early
onset cases may have higher heritability. We recently showed
stronger effects for all stroke-associated SNPs in younger age
groups, found evidence genome-wide that a significant number of
SNPs show stronger association p-values when the oldest cases are
removed, and showed increased pseudoheritability estimates for
younger onset cases in certain stroke subtypes, thereby supporting
this hypothesis [14]. However, the question of how best to
integrate this information into GWAS analyses of ischaemic stroke
remains unanswered. Previous GWAS have analysed younger
subsets of ischaemic stroke cases [1,15], but this approach may not
be optimal for existing GWAS datasets if the increase in odds
ratios for SNPs in younger cases are not sufficient to justify
discarding a large proportion of the ascertained cases. All previous
young onset analyses have been restricted to all ischaemic stroke
cases versus controls; this may be particularly relevant given that
all known loci for ischaemic stroke to date are for stroke subtypes
[16].
A recent publication [17], outlined a novel method of
informing genetic association analyses on important clinical
covariates. Using the liability threshold model in conjunction
with estimates of disease prevalence for individuals with specific
clinical covariates, the method estimates posterior disease
liabilities for each individual in a GWAS, and uses these
liabilities in regression analyses to test for association with
genome-wide SNPs. This approach avoids issues due to multiple
testing across age-at-onset thresholds, and provides a simple
solution that is rooted is previous epidemiological research. In
the present study, we extend the clinical covariate informed
analysis approach to imputed genotypes, informing our analyses
on the age-at-onset to identify novel variants associated with IS.
We perform a genome-wide analysis with four stroke pheno-
types (IS, CE, LAA, SVD), and then determine the utility of the
approach in ischaemic stroke GWAS, testing whether SNPs
increase in significance.
Results
Association analysis
We performed age-at-onset informed association analysis for a
total of 6,778 ischaemic stroke cases and 12,095 controls across
four ischaemic stroke phenotypes; all IS and the three major
subtypes: CE, LAA, and SVD (Table 1); with 1,637, 1,316, and
1,108 cases in the CE, LAA and SVD analyses respectively. With
the exception of the young Milanese cohort, the age-at-onset
distributions were similar in all cohorts (Table S3).
We identified a group of twenty SNPs proximal to MMP3 and
MMP12 on chromosome 11 in the LAA subtype that met our
criteria for replication. The strongest associated of these was
rs662558 (p = 1.461027), a SNP that is in 1000 Genomes, but not
HapMap II. Therefore, to enable replication in existing METAS-
TROKE datasets, which were imputed to HapMap II, we selected
the most strongly associated SNP from the HapMap II panel,
which was in perfect LD with the lead SNP in our discovery meta-
analysis (rs660599: uninformed, p = 1.661026; informed,
p = 2.561027; Figure 1) [16]. We found no evidence of
between-study heterogeneity at either SNP (Cochran’s Q
p= 0.22 and p= 0.19 for rs662558 and rs660599, respectively).
The evidence of an age-at-onset effect at rs660599 was p= 0.011
(from permutations). We calculated age-at-onset quartiles for all
large artery stroke cases from the discovery cohorts, and used these
to evaluate this region at different age-at-onset thresholds. The
median age-at-onset was 71 years, and the interquartile range was
between 61 and 78 years. Post-hoc analyses of rs660599 in the
discovery cohorts using logistic regression (full details in Text S2)
showed considerably stronger associations in younger age-at-onset
quantiles (Q1; OR(95% CI) = 1.83 (1.46–2.30), Q1–Q2; 1.56
(1.33–1.83), Q1–Q3; 1.30 (1.14–1.49), Q1–Q4; 1.30 (1.15–1.46)).
No other regions met our criteria for replication.
Replication analysis
The associated locus was evaluated in a further 1,881 large artery
stroke cases and ancestry matched controls in 9 cohorts from
METASTROKE (Table 2). We found evidence for replication of
the SNP (rs660599) in all large artery stroke cases of European
Ancestry (p= 0.0048, OR(95% CI)= 1.18(1.05–1.32)). Combining
this result with the discovery p-value gave a genome-wide significant
p-value of 2.661028 (Table 3). Secondly, we used the Han and
Eskin random effects meta-analysis approach to evaluate the
association [18] after including a further 355 cases and 1,390
controls of Pakistani ancestry. The evidence for replication in this
sample was p= 0.0063, giving an overall p-value of 3.461028. Age-
at-onset information was available across all age-at-onset quantiles
for a subset of the replication studies (1,240 cases, 9,238 controls;
ASGC, HVH, ISGS/SWISS, MGH-GASROS, Utrecht). We
evaluated the SNP (rs660599) in these studies at different age-at-
onset quantiles using logistic regression, meta-analysing as previ-
ously. We again found the strongest effects in the youngest age
quantile, consistent with a stronger effect in younger onset cases
(Q1; OR(95% CI)= 1.27(1.02–1.57), Q1–Q2; 1.18(1.00–1.39),
Q1–Q3; 1.22(1.05–1.40), Q1–Q4; 1.22(1.07–1.41)).
mRNA expression in carotid plaques
mRNA expression of the two proximal genes, MMP3 and
MMP12 was analysed from 29 carotid, 15 abdominal aorta, 24
femoral plaques, and 28 atherosclerosis free left internal thoracic
artery controls. MMP12 expression was upregulated in carotid
plaques compared with left internal thoracic artery controls
(P = 1.2610215; fold change [FC]= 335.6). It was also upregulated
in femoral plaques (P = 3.2610214; FC= 306.0) and abdominal
Author Summary
Ischaemic stroke places an enormous burden on global
healthcare. However, the disease processes that lead to
stroke are not fully understood. Genome-wide association
studies have recently established that common genetic
variants can increase risk of ischaemic stroke and its
subtypes. In this study, we aimed to identify novel genetic
associations with ischaemic stroke and its subtypes by
addressing the fact that younger onset cases may have a
stronger genetic component, and using this information in
our analyses. We identify a novel genetic variant on
chromosome 11 (rs660599), which is associated with
increased risk of large artery stroke. We also show that
mRNA expression of the nearest gene (MMP12) is higher in
arteries with the disease process underlying large artery
stroke (atherosclerosis). Finally, we evaluate our novel
analysis approach, and show that our method is likely to
identify further associations with ischaemic stroke.
MMP12 and Large Artery Atherosclerotic Stroke
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plaques (P = 5.0610211; FC= 399.3) compared with controls.
Conversely,MMP3 was not significantly overexpressed in carotid,
femoral or abdominal plaques versus controls (p.0.05).
Regulatory information from ENCODE
Eight SNPs were identified that were perfect proxies (r2 = 1)
with the associated SNP (rs660599) in the region. Seven of the
SNPs were in an intergenic region between MMP3 and MMP12,
while one fell within an intron of MMP12. We investigated the
evidence that any of these SNPs are functional variants using
RegulomeDB [19]. Of the eight SNPs, we found strong evidence
that one of these SNPs (rs586701) affects binding. The SNP
overlaps both CHIP-seq and DNA-seq peaks from ENCODE
analyses, indicating that there is open chromatin in the region, and
therefore that the SNP is likely to be functional. There is also
evidence from a separate CHIP-seq analysis that the SNP affects
protein binding [20], and evidence from multiple sources that the
SNP overlaps a predicted motif [21,22,23]. Histone modifications
were observed in CHIP-seq experiments from ENCODE in a
number of cells types, including Human umbilical vein endothelial
(Huvec) cells. Two other SNPs (rs17368582, rs2276109) in
moderate LD with the associated SNP (r2 = 0.64) have been
previously shown to directly influence MMP12 expression by
affecting the affinity of an AP-1 binding site in the MMP12
promoter region [24,25]. Using RegulomeDB, we found further
evidence from ENCODE that one of these SNPs (rs2276109) is
indeed functional, giving evidence that the associated locus in this
analysis is likely to affect MMP12 expression through altered
Table 1. Sample size of discovery populations.
Study Population IS CE LAA SVD Controls
Belgium – Immunochip 396 147 57 49 319
Germany-Immunochip 421 127 101 - 2,355
Krakow – Immunochip 384 119 33 28 255
Sweden – Immunochip 796 246 56 183 997
UK – Immunochip 867 130 152 257 1,790
Germany – WTCCC2 1,174 330 346 106 797
UK – WTCCC2 2,374 474 498 460 5,175
Milano 366 64 73 25 407
Total (Discovery) 6,778 1,637 1,316 1,108 12,095
IS, all ischaemic stroke; CE, cardioembolic stroke; LAA, large artery stroke; SVD, small vessel disease.
doi:10.1371/journal.pgen.1004469.t001
Figure 1. LocusZoom plot of MMP12 association using age-at-onset informed approach. SNPs are colored based on their correlation (r2)
with the labeled top SNP, which has the smallest P value in the region. The fine-scale recombination rates estimated from 1000 Genomes (EUR) data
are marked in light blue, with genes marked below by horizontal blue lines. Arrows on the horizontal blue lines show the direction of transcription,
and rectangles are exons. SNP p-values are from the discovery meta-analysis only with the exception of rs660599, for which the given p-value
indicates the overall evidence for association from the discovery and replication cohorts.
doi:10.1371/journal.pgen.1004469.g001
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transcription. Detailed results for all analysed SNPs are given in
Table S1. Additionally, we investigated if these SNPs (rs17368582,
rs2276109, rs586701) were associated with MMP12 expression in
tissues from the GTEx project [26]. However, we could not
confirm an association with MMP12 expression in any relevant
tissues (p.0.4 in whole blood, tibial artery, aortic artery).
Evaluation of age-at-onset informed approach
Finally, we evaluated the overall utility of the age-at-onset
informed approach in permutation analyses for SNPs that met p-
value thresholds in the case control discovery data set. We
generated 1000 permutations of age-at-onset within each centre,
and performed age-at-onset informed analysis and subsequent
meta-analysis for these SNPs, in the relevant stroke subtype.
We compared the sum of the meta-analysis Z scores from all
SNPs with p,0.05 in the observed age at onset informed meta-
analysis with those from permutations. At this p-value selection
threshold, we found strong evidence (p,0.001) for genome-wide
age-at-onset effects in each of the stroke phenotypes, with
consistently increased summed Z scores in the observed age-at-
onset informed meta-analysis compared to the permutations
(Figure 2, red points, right hand axis). These results suggest that
many of the risk variants for each stroke subphenotype have a
higher frequency in younger onset cases. As the p-value selection
threshold decreased, the summed Z score statistic became less
significant in each stroke type, possibly reflecting lower overall
power when fewer SNPs are included, even as these SNPs may
have larger average effects. Further details are seen from the
median proportion of SNPs more significant in the age-at-onset
informed analysis than in the permutations (Figure 2, blue points,
left hand axis). For CE and LAA stroke, the proportions increased
with more stringent p-value thresholds (from 52.1% to 56.3% for
p,0.05 and p,0.00005 thresholds in CE, and from 51.4% to
56.0% for p,0.05 and p,0.00005 thresholds in LAA). Interest-
ingly, in the all ischaemic stroke analysis the median proportion of
SNPs more significant in the observed results than permutations
dropped from 55.1% for SNPs with p,0.05 to 49.2% for only
SNPs with p,0.00005. This result may indicate a reduced
proportion of true associations at stricter p-value thresholds for all
ischaemic stroke compared to the subtypes, which is consistent
with the observation that all common variants associated with
stroke are for stroke subtypes, rather than for the phenotype of all
ischaemic stroke [16].
The previously reported GWAS associations from a recent
ischaemic stroke meta-analysis (9p21, HDAC9, PITX2, ZFHX3)
were all found to be more significant using the age-at-onset
informed approach than the uninformed analysis (Figure 3). The
increase in significance ranged from over half an order of
Table 2. Sample size of replication populations.
Study Population LAA (age,61) LAA (age,71) LAA (age,78) LAA (all ages) IS Controls
ARIC - - - 31 385 8,803
ASGC 81 179 277 421 1,162 1,244
deCODE - - - 255 2,391 26,970
GEOS - - - 37 448 498
HVH 18 39 63 71 566 2,072
ISGS/SWISS 84 130 179 217 1,070 1,370
MGH-GASROS (Affymetrix) 31 60 79 102 485 3,030
MGH-GASROS (Illumina) 22 47 59 68 296 377
PROMISe 134 230 301 324 556 1,145
RACE - - - 355 1,390 5,308
Total (Replication) 370 685 958 1,881 8,749 50,817
LAA, large artery stroke; IS, all ischaemic stroke; ARIC, the Atherosclerosis Risk in communities study; ASGC, the Australian Stroke Genetics collaboration; deCODE,
deCODE genetics; GEOS, the Genetics of early onset stroke study; HVH, the heart and vascular health study; ISGS/SWISS, the Ischaemic stroke genetics study/Siblings
with Ischaemic stroke study; MGH-GASROS, Massachusetts General Hospital – Genetics affecting stroke risk and outcome; PROMISe, Prognostic modeling in ischaemic
stroke study [55]; RACE, Risk Assessment of Cerebrovascular Events study. For further details of these populations please see the original METASTROKE publication [16].
doi:10.1371/journal.pgen.1004469.t002
Table 3. Evidence for association of A allele of rs660599 (chromosome 11; Base position 102,234,967) with large artery
atherosclerotic stroke and all ischaemic stroke.
Subtype SNP RAF p-value (discovery)
OR (95% CI) (EUR
replication)
p-value (EUR
replication, overall)
p-value (ALL
replication, overall)
LAA rs660599 0.19 2.5.61027 1.18 (1.05–1.32) 0.0048, 2.661028 0.0063, 3.461028
IS ‘‘ ‘‘ 3.261024 1.05 (1.00–1.11) 0.050, 1.961024 0.098, 3.661024
CE ‘‘ ‘‘ 0.13 - - -
SVD ‘‘ ‘‘ 0.30 - - -
LAA, large artery stroke; IS, all ischaemic stroke; SNP, single nucleotide polymorphism; RAF, risk allele frequency; OR, odds ratio; 95% CI, 95% confidence interval; EUR,
meta-analysis in individuals of European ancestry alone; ALL, trans-ethnic meta-analysis of all individuals. Forest plots of effect sizes and standard errors for each
replication centre are given in Figures S3, S4.
doi:10.1371/journal.pgen.1004469.t003
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magnitude (7.961029 to 1.561029 for rs879324 in ZFHX3,
CE), to under half an order of magnitude (5.761029 to
2.561029 for rs2107595 in HDAC9, LVD). To ensure these
analysis methods were comparable, we calculated genomic
inflation factors and plotted QQ-plots. These were similar in
the standard and the age-at-onset informed approach (Table
S4, Figure S1, S2). For these four associated SNPs, we further
used the permuted data sets to assess the observation of
increased significance in the age-at-onset informed analysis.
We compared the observed meta-analysis p-value to those
from the permutations, generating an empirical p-value by
dividing the number of permutations more significant than the
observed results by the number of permutations. In LAA
stroke, we observed a significant age-at-onset effect (p = 0.018,
0.011 and 0.002 for the HDAC9, MMP12 and 9p21-
associated SNPs in Figure 3, respectively). Similarly, for CE,
we observed a significant age-at-onset effect for rs879324
(ZFHX3, p = 0.026), and a near-significant effect in rs6843082
(PITX2, p = 0.081). This result provides further evidence that
risk variants associated with ischaemic stroke subtypes have a
stronger role in younger onset cases, and suggests that the age-
at-onset informed approach will produce improved signifi-
cance when the magnitude of genetic effects are stronger in
younger onset cases.
Discussion
We used a large GWAS dataset to evaluate the utility of an age-
at-onset informed analysis approach to ischaemic stroke, and to
identify novel variants associated with ischaemic stroke pheno-
types. We identified a novel MMP12 locus that is associated with
large artery atherosclerotic stroke, and verified that the age-at-
onset informed approach produces improved significance for loci
associated with each of the stroke phenotypes studied, as well as
demonstrating that it increased the significance of four previous
GWAS associations with ischemic stroke, all without systematic
inflation of the test statistic. Importantly, the novel associated SNP
would not have been identified using a standard logistic regression
framework.
We identified a group of SNPs proximal to Matrix Metallo-
proteinase 12 (MMP12) that showed increased significance when
using the age-at-onset informed approach. The increase in
significance from the equivalent uninformed analysis was of
almost an order of magnitude (from p= 1.661026 to
p= 2.561027 for rs660599). We took a single SNP from this
region forward for replication in an independent dataset, finding
further evidence that the region is associated with large artery
stroke. Two SNPs (rs17368582, rs2276109) in this LD-block have
previously been shown to directly influenceMMP12 expression by
Figure 2. Evaluation of evidence genome-wide for SNPs exhibiting greater significance using the age-at-onset informed approach
compared to permutations. -log10(p value) from permutations for evidence of age-at-onset effect at given SNP p-value selection threshold
shown in red; median proportion of SNPs (with IQR) more significant in observed age-at-onset informed meta-analysis compared to permutations
shown in blue; horizontal line at p = 0.05 in red; horizontal line at median proportion of SNP = 0.5 in blue; IS, all ischaemic stroke; CE, cardioembolic
stroke; LAA, large artery atherosclerotic stroke; SVD, small vessel disease. See Table S5 for number of SNPs included at each p-value selection
threshold.
doi:10.1371/journal.pgen.1004469.g002
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affecting the affinity of an AP-1 binding site in the MMP12
promoter region [24,25], and another variant in this block
(rs17361668) is associated with increased fibrinogen levels, leading
to an increased risk of developing advanced carotid atherosclerotic
lesions, and an increased risk of myocardial infarction. We
identified a second functional candidate (rs586701), which falls
within both CHIP-seq and DNA-seq peaks from ENCODE, and is
in complete LD with the associated SNP in our analysis.
We investigated mRNA expression of MMP12 and MMP3 in
carotid atherosclerotic plaques in individuals from the Tampere
Vascular Study. MMP12 was overexpressed in diseased tissue
compared to healthy controls, while no significant difference was
found for the other nearby gene,MMP3.MMP12 is a member of
the Matrix Metalloproteinase (MMP) family of proteases, which
are capable of degrading extracellular matrix proteins, and have a
prominent role in atherosclerosis. They are thought to promote
macrophage invasion [27,28,29], promote angiogenesis [30], and
show increased activity in atheromatous plaques [31]. MMP12
deletions are associated with smaller, more stable lesions in the
brachiocephalic artery of rabbits [32], and reduced elastin
degradation in the aortic arch [33], indicating that MMP12
may have a role in destabilising plaques. Studies in humans have
found MMP12 is localized to the core of advanced plaques, in
macrophages with decreased arginase-I expression [34], that
MMP12 localizes selectively to macrophages at the borders of the
lipid core [35], and that MMP12 is significantly overexpressed in
ruptured plaques when compared with thick or thin cap plaques,
or with plaques with pathological intimal thickening [36]. This
indicates that MMP12 is likely be involved in late-stage plaque
instability: our study suggests that genetic variation impacts on this
process.
Secondly, we performed extensive permutation analyses to
assess the utility of the age-at-onset informed approach genome-
wide. In each phenotype studied we found evidence that SNPs
were more strongly associated using the approach than would be
expected by chance, indicating that multiple risk variants are likely
to be more common in younger onset cases. The significance was
strongest when more SNPs were included in the analysis, which
likely reflects the cumulative impact of age-at-onset effects on
many SNPs. An alternative explanation might be that the
increased significance for lower p-value thresholds is the result of
the cumulative effects of subtle confounding. However, this is
unlikely because any subtle biases will also be present in the
permutations, and should therefore not affect the significance of
the results. This result supports observations from family history
and prospective cohort studies, which have observed stronger
effects in younger onset cases [6,11]. Furthermore, all known
associations with stroke were more significant using the age-at-
onset informed approach. The increase in significance was around
half an order of magnitude (e.g from p= 7.961029 to 1.561029
for ZFHX3, Figure 2), and was significant in all but one locus, as
assessed by permutation. Taken together, these results indicate
that age-at-onset is an important measure to stratify stroke cases,
and show that, as expected by theory [17], integrating this
information into association studies is likely to increase power to
identify novel loci when the relative contribution of genetic is
dependent on age-at-onset.
Our study has limitations. We used imputed data from the
Immunochip platform, meaning we only had access to ,40% of
the genome across all centres. Secondly, cases were drawn from a
number of international centres, meaning that despite efforts to
standardize phenotyping, we cannot rule out differences in
screening and clinical ascertainment.
Of complex diseases, IS has a particularly large degree of
heterogeneity, exemplified by the fact that all validated associa-
tions identified to date have been within subtypes defined by
clinical and radiological information. Further heterogeneity by risk
factor and clinical covariate profiles is likely to exist, but the
optimal method of incorporating this information into analyses
remains an unanswered question. Our results indicate that a
Figure 3. Meta-analysis p-values of known loci for ischaemic stroke subtypes using age-at-onset informed approach compared to
uninformed approach. -log10 of p-values derived from meta-analysis of all discovery cohorts using age-at-onset informed approach (red) and
uninformed approach (blue). 9p21 (rs1004638), MMP12 (rs660599) and HDAC9 (rs2107595) p-values calculated within large artery atherosclerosis
subtype of stroke, PITX2 (rs6843082) and ZFHX3 (rs879324) p-values calculated with cardioembolic stroke subtype.
doi:10.1371/journal.pgen.1004469.g003
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covariate-informed design, conditioning on age-at-onset of stroke,
can unearth further associated variants. We provide evidence for
this by identifying an association with a novel MMP12 locus in
large artery stroke, supported by increased mRNA expression of
the implicated gene in carotid plaques. GWAS in ischaemic stroke
have begun to identify the genetic component of the disease, but
these results are not yet clinically useful. Our study suggests that a
more refined approach to analysis of genetic data, incorporating
covariate information, is an important step in this process, and will
help to ensure success in future GWAS.
Materials and Methods
Ethics statement
All studies were approved by their local ethics committees; all
patients gave informed consent.
Description of datasets
The initial dataset consisted of 6,778 ischaemic stroke cases of
European ancestry and 12,095 ancestry-matched controls from
the Wellcome Trust Case-Control Consortium II project in
ischaemic stroke [1], as well as a cohort from Milan, Italy [16].
These included 2,858 cases and 5,716 matched controls genotyped
using the Immunochip platform; and 3,940 cases genotyped using
either the Illumina 610 k or 660 k platforms matched with 6,379
controls genotyped on the Illumina Human 1.2M Duo (UK),
Illumina Human 550 k (German) and Illumina 610 k platforms
(Italian) (Table 1). The Immunochip cases were described in the
previous WTCCC2 ischaemic study, where they formed the
replication effort [1], as well as in a recent paper [37]. Genotyping
of the five Immunochip case cohorts on the commercially available
Immunochip array (Illumina, San Diego, CA, USA) was
performed at the Sanger Centre, Hinxton, Cambridge UK.
Swedish controls were provided and genotyped by the Swedish
SLE network, Uppsala, Sweden. Belgian control samples were
provided through the efforts of the International Multiple Sclerosis
Genetics Consortium (IMSGC). German controls were derived
from the PopGen biobank, [38]. UK controls were derived from
the 1958 Birth cohort. Any of the 1958 Birth controls overlapping
with those from the WTCCC2 datasets, as assessed by IBD
estimates, were removed prior to analysis. Standard quality control
procedures were undertaken on all centres, before centre-wise
imputation to the 1000 Genomes phase 1 integrated variant set
(March 2012), using IMPUTE v2.2.0 [39,40]. SNPs with poor
imputation quality (info,0.3) or low minor allele frequency
(MAF,0.01) were discarded.
Ischemic stroke was defined as a typical clinical syndrome with
radiological confirmation; ascertained cases were classified into
individual stroke subtypes using the Trial of Org 10172 in acute
stroke (TOAST) criteria in all centres [41]. Age-at-onset was
defined as age at first hospital admission for stroke; where this
information was unavailable, age at blood draw was used (7.3% of
cases). The age-at-onset and gender distributions of the popula-
tions are given in Table S3. Age-at-onset quantiles were calculated
from all the cases from the discovery datasets in the four stroke
phenotypes (all IS and the three stroke subtypes: CE, LAA, SVD)
and these were used to evaluate associated loci at different age-at-
onset thresholds.
Association analysis
The prevalence of ischaemic stroke by age was obtained from a
recent publication [9]; gender-specific estimates were averaged,
and prevalences within each of the stroke subtypes were assumed
to be approximately 20% of the overall total, similar to
proportions seen in population-based studies [42]. We modeled
phenotype data using a continuous unobserved quantitative trait
called the disease liability, which we used to approximate the
effect of age-at-onset on the liability scale, based on estimates of
ischaemic stroke prevalence by age from epidemiological data
(full details in Text S2). We developed two models for our
analysis; one based on the prevalence rates for all ischaemic
stroke cases, and secondly for the three stroke subtypes. We used
these models to calculate posterior mean liabilities after condi-
tioning on age-at-onset for the four stroke phenotypes separately.
Controls were modeled in the same way, but were assumed to
take the posterior mean from the lower (unaffected) portion of the
distribution in the liability threshold model. Where age data was
missing, individuals were assigned the median age value. Full
descriptions of the models used and the formulae used to
calculate posterior mean liabilities are given in Text S2.
Regression was then performed on posterior liabilities by
multiplying the number of samples by the squared correlation
between the expected genotype dosage and posterior mean
liabilities for each of the discovery cohorts in the four ischaemic
stroke phenotypes (CE, LAA, SVD, IS), following a previous
approach [17]. Ancestry-informative principal components were
included where appropriate (6 of 8 centres), using the EIGEN-
STRAT procedure [43]. All analysis was performed using the R
statistical software.
The results from each centre were meta-analysed for each of the
four phenotypes using Stouffer’s Z-score weighted approach, as
implemented in METAL [44]. Genomic control was used to
correct for any residual inflation due to population stratification
[45]. Between-study heterogeneity was assessed using Cochran’s Q
statistic. We considered only SNPs present in at least 75% of the
cases, and with no evidence of heterogeneity (Cochran’s Q p-
value.0.001). All SNPs analysed were either genotyped or
imputed in both the Immunochip and the genome-wide datasets.
After meta-analysis, the resulting p-values were compared with the
equivalent values from an unconditioned analysis. For SNPs more
significant in the age-at-onset informed analysis and with p,
561026, we determined the evidence of a true age-at-onset effect
by generating 1000 permutations of age-at-onset and rerunning
the age-at-onset informed analysis, meta-analysing as previously.
We calculated an empirical p-value by dividing the number of
permuted observations showing greater significance in the meta-
analysis than the observed results by the number of permutations.
Any novel SNP with a meta-analysis p,561026 and evidence of
an age-at-onset effect at p,0.05 were taken forward for
replication. We set the experiment-wide significance threshold at
p,561028.
Replication analysis
Replication of an associated variant was performed in a further
10 cohorts from METASTROKE. Nine of the centres used a
cross-sectional design, while one was a large prospective,
population based cohort (ARIC). Nine of the centres were of
European ancestry, while one consisted of individuals of Pakistani
ancestry (RACE) (Table 2). All centres used a case-control
methodology; centres with a cross sectional design used logistic
regression to model the association of genotype dosages from
imputation with the dichotomous outcome of ischaemic stroke and
prospective cohorts used Cox proportional-hazards models to
evaluate time to first stroke, fitting an additive model relating
genotype dose to the stroke outcome. European ancestry
replication centres were meta-analysed using a fixed effects
inverse-variance weighted method. To assess the evidence for
association of the SNP for replication samples of all ancestries, we
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performed a trans-ethnic meta-analysis using a random-effects
model to control for any resulting heterogeneity [18]. To evaluate
the overall evidence for association, the results of the discovery and
replication analyses were combined using Fisher’s Method.
mRNA expression in carotid atherosclerotic plaques
Expression of the two genes proximal to the associated variant
was tested in atherosclerotic plaques from the Tampere Vascular
study [27,46,47,48,49]. Carotid, femoral, and aortic atheroscle-
rotic plaques constituting the intima and inner media were
prospectively obtained between 2005 and 2009 from patients
fulfilling the following inclusion criteria: (1) carotid endarterecto-
my attributable to asymptomatic or symptomatic .70% carotid
stenosis, or (2) femoral or (3) aortic endarterectomy with aortoiliac
or aortobifemoral bypass attributable to symptomatic peripheral
arterial disease. Whole thickness left internal thoracic artery
samples obtained during coronary artery bypass surgery and
identified as being microscopically atherosclerosis free were
used as controls. The patients were consecutively recruited
and stratified according to indication for surgery. All open
vascular surgical procedures were performed at the Division
of Vascular Surgery and Heart Center, Tampere University
Hospital.
Fresh tissue samples were immediately soaked in RNALater
solution (Ambion Inc) and homogenized using an Ultra-Turrax
T80 homogenizer (IKA). RNA was extracted with the Trizol
reagent (Invitrogen) and miRNEasy Mini-Kit (Qiagen) with the
RNase-Free DNase Set (Qiagen) according to manufacturer
instructions. The RNA isolation protocol was validated by
analyzing the integrity of the RNA with the RNA 6000 Nano
Chip Kit (Agilent). The expression levels were analyzed with an
Illumina HumanHT-12 v3 Expression BeadChip (Illumina). In
brief, 300–500 ng of RNA was reverse transcribed in cRNA and
biotin-UTP labeled using the IlluminaTotalPrep RNA Amplifica-
tion Kit (Ambion), and 1500 ng of cRNA was then hybridized to
the Illumina HumanHT-12 v3 Expression BeadChip.
The BeadChips were scanned with the Illumina iScan system.
After background subtraction, raw intensity data were exported
using the Illumina Genome Studio software. Further data
processing was conducted by means of R language and appropriate
Bioconductor modules. Data were log2-transformed, and robust
multichip average and robust spline normalization (rma_rsn) were
used. Accuracy of the expression array was validated with qRT-
PCR [50]. mRNA Expression levels in the tissues were determined;
a fold change statistic was estimated between the two tissues, and
significance was calculated using a t test.
Regulatory information using RegulomeDB
Recent evidence indicates that a significant proportion of
GWAS SNPs fall within regions that are likely to affect binding of
nearby proteins, such as transcription factor binding sites [51,52].
We used the RegulomeDB database to access regulatory
information from ENCODE and other existing publications
[19], investigating the evidence that the SNPs in the associated
locus have a regulatory function. First, the linkage-disequilibrium
(LD) patterns amongst the most strongly associated SNPs were
determined. We then used PLINK to determine the LD structure
of the associated region, using LD-patterns from the 85 Utah
residents from the 1000 Genomes project [53,54]. All SNPs with
r2.0.6 were identified within a 2,000 kb window from the index
SNP. All of the SNPs identified were then investigated using
RegulomeDB to determine the evidence that any of the SNPs have
a regulatory function.
Evaluation of age-at-onset informed approach
Permutation analysis was performed to evaluate the age-at-
onset informed approach, to show that including age at onset
information directly led to the increased significance, due solely
to inclusion of age-at-onset information at tested SNPs. First, we
identified a set of SNPs enriched for true association in the case
control analysis of ischaemic stroke and subtypes. An expanded
set of discovery and METASTROKE studies were analysed
using standard case control methods and subsequent meta-
analysis (see Table S2). SNPs with p,0.05 and no evidence of
heterogeneity (p.0.0001) were extracted and pruned for LD
(300 kb window, r2,0.25), leaving a set of almost independent
SNPs for further analysis. Each retained SNP represented the
most significant association in each LD block, as determined by
the ‘‘clump’’ procedure in PLINK, based on LD patterns from
the CEU individuals from 1000 Genomes. The number of SNPs
used in each analysis is given in Table S5. These SNP subsets
were derived for ischaemic stroke, and for each stroke subset
and then used in the age-at-onset informed analysis. Analysis
was performed as previously for each stroke subtype using the
age-at-onset informed method within studies and meta-analysis
across studies (giving observed results, as obtained above). We
then performed a permutation study to obtain the expected
distribution of p-values at these SNPs. Age at onset for cases was
permuted within stroke subtypes within each study, and then the
data were re-analysed, for 1000 permutations. Two summary
statistics were constructed: (1) within permutations, we com-
pared p-values from analysis of permuted age at onset with p-
values from the observed data, and tabulated the proportion of
SNPs with increased significance in the observed data set than
in the permuted data set; across permutations, we calculated the
median proportion of SNPs with increased significance in the
observed data; (2) Within permutations, we converted each SNP
p-value to a Z score and summed the absolute value of the Z
score across SNPs (sumZ). An empirical p-value for the age-
informed analysis was calculated from the proportion of
simulated data sets where sumZ exceeded the value in the
observed analysis. This analysis was performed at SNP subsets
defined from four SNP p-value thresholds in the discovery and
METASTROKE studies: p,0.05, p,0.005, p,0.0005, and
p,0.00005.
Finally, we assessed the evidence of an age-at-onset effect at the
four stroke loci identified in the METASTROKE ischaemic stroke
collaboration (9p21, HDAC9, PITX2, ZFHX3) [16]. For each
SNP, we generated an empirical p-value from the proportion of
permutations showing stronger association than in the observed
age-at-onset informed analysis.
Supporting Information
Figure S1 QQ-plots for cardioembolic stroke and all ischaemic
stroke analyses. QQ-plots of expected p-values (x-axis) against
observed p-values (y-axis) for analyses of (clockwise from top left)
cardioembolic stroke (age-at-onset informed), cardioembolic stroke
(uninformed), all ischaemic stroke (uninformed), all ischaemic
stroke (age-at-onset informed). Lambda values for each plot are
given in Table S4.
(DOCX)
Figure S2 QQ-plots for large artery atherosclerotic stroke and
small vessel disease stroke analyses. QQ-plots of expected p-values
(x-axis) against observed p-values (y-axis) for analyses of (clockwise
from top left) large artery stroke (age-at-onset informed), large
artery stroke (uninformed), small vessel stroke (uninformed), small
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vessel stroke (age-at-onset informed). Lambda values for each plot
are given in Table S4.
(DOCX)
Figure S3 Forest plot of SNP effects for rs660599 in the large
artery atherosclerotic stroke replication populations. ASGC,
the Australian Stroke Genetics collaboration; deCODE,
deCODE genetics; GEOS, the Genetics of early onset stroke
study; HVH, the heart and vascular health study; ISGS/
SWISS, the Ischaemic stroke genetics study/Siblings with
Ischaemic stroke study; MGH-GASROS, Massachusetts Gen-
eral Hospital – Genetics affecting stroke risk and outcome.
PROMISe, Prognostic modeling in ischaemic stroke study;
RACE, Risk Assessment of Cerebrovascular Events study.
(DOCX)
Figure S4 Forest plot of SNP effects for rs660599 in the large
artery atherosclerotic stroke replication populations for cases
with age ,61 years. ASGC, the Australian Stroke Genetics
collaboration; HVH, the heart and vascular health study;
ISGS/SWISS, the Ischaemic stroke genetics study/Siblings
with Ischaemic stroke study; MGH-GASROS, Massachusetts
General Hospital – Genetics affecting stroke risk and
outcome. PROMISe, Prognostic modeling in ischaemic stroke
study.
(DOCX)
Table S1 Results from RegulomeDB, showing the evidence
that SNPs in the associated MMP12 region have a regulatory
function. Scores indicate the following degrees of evidence:
Score 2b, TF binding + any motif + DNase Footprint + DNase
peak; Score 4, TF binding + DNase peak; Score 5, TF binding
or DNase peak; Score 6, other; ‘‘No data’’ indicates that
RegulomeDB holds no information about the given SNP,
meaning there currently exists no evidence to suggest that the
SNP has a regulatory function. In some cases this may indicate
that the SNP falls within a protein-coding region. SNP, single
nucleotide polymorphism.
(DOCX)
Table S2 Expanded set of populations used to generate SNPs
with p,0.05 to evaluate the age-at-onset informed approach.
ARIC, The Atherosclerosis Risk in Communities study; ASGC,
Australian Stroke Genetics Collaborative; CHS, Cardiovascular
Health Study; FHS, Framingham Heart Study; HPS, Heart
Protection Study; HVH, The Heart and Vascular Health Study;
ISGS/SWISS, The Ischemic Stroke Genetics Study/Sibling
with Ischaemic Stroke Study; MGH-GASROS, The MGH
Genes Affecting Stroke Risk and Outcome Study; WTCCC2-
Germany, The Wellcome Trust Case-Consortium II Munich;
WTCCC2-UK, The Wellcome Trust Case-Consortium II UK;
RACE, Risk Assessment of Cerebrovascular Events Study,
Pakistan.
(DOCX)
Table S3 Age and gender distributions of populations. ARIC,
The Atherosclerosis Risk in Communities study; ASGC, Austra-
lian Stroke Genetics Collaborative; CHS, Cardiovascular Health
Study; FHS, Framingham Heart Study; HPS, Heart Protection
Study; HVH, The Heart and Vascular Health Study; ISGS/
SWISS, The Ischemic Stroke Genetics Study/Sibling with
Ischaemic Stroke Study; MGH-GASROS, The MGH Genes
Affecting Stroke Risk and Outcome Study; WTCCC2-Germany,
The Wellcome Trust Case-Consortium II Munich; WTCCC2-
UK, The Wellcome Trust Case-Consortium II UK; RACE, Risk
Assessment of Cerebrovascular Events Study, Pakistan. IS, all
ischaemic stroke; CE, cardioembolic stroke; LAA, large artery
stroke; SVD, small vessel disease.
(DOCX)
Table S4 Genomic inflation (l) rates for discovery populations
for age-at-onset informed and uninformed approaches. IS, all
ischaemic stroke; CE, cardioembolic stroke; LAA, large artery
stroke; SVD, small vessel disease.
(DOCX)
Table S5 Number of SNPs used in evaluation of age-at-onset
informed approach. IS, all ischaemic stroke; CE, cardioembolic
stroke; LAA, large artery stroke; SVD, small vessel disease.
(DOCX)
Text S1 Membership of Wellcome Trust Case Control Consor-
tium 2 (WTCCC2).
(DOCX)
Text S2 Liability threshold models.
(DOCX)
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